Filing Details

Accession Number:
0001415889-24-020687
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-02 19:25:05
Reporting Period:
2024-07-31
Accepted Time:
2024-08-02 19:25:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967168 Samuel Kintz C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-07-31 2,270 $27.56 1,061,255 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 0 Indirect See footnote
Common Stock 0 Indirect See footnote
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
  4. The Reporting Person does not have direct or indirect beneficial ownership of shares that were previously reported as held by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son as the Reporting Person does not have any control over such trust and therefore does not directly or indirectly beneficially own shares held by such trust.
  5. The Reporting Person does not have direct or indirect beneficial ownership of shares that were previously reported as held by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son as the Reporting Person does not have any control over such trust and therefore does not directly or indirectly beneficially own shares held by such trust.